BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25825601)

  • 1. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.
    Wester HJ; Keller U; Schottelius M; Beer A; Philipp-Abbrederis K; Hoffmann F; Šimeček J; Gerngross C; Lassmann M; Herrmann K; Pellegata N; Rudelius M; Kessler H; Schwaiger M
    Theranostics; 2015; 5(6):618-30. PubMed ID: 25825601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
    Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
    Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer
    Hyafil F; Pelisek J; Laitinen I; Schottelius M; Mohring M; Döring Y; van der Vorst EP; Kallmayer M; Steiger K; Poschenrieder A; Notni J; Fischer J; Baumgartner C; Rischpler C; Nekolla SG; Weber C; Eckstein HH; Wester HJ; Schwaiger M
    J Nucl Med; 2017 Mar; 58(3):499-506. PubMed ID: 27789718
    [No Abstract]   [Full Text] [Related]  

  • 4. Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.
    Yang T; Shi D; Lin Q; Shen H; Tan H; Liu Y; Shi H; Cheng D
    Mol Pharm; 2024 May; 21(5):2415-2424. PubMed ID: 38606663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.
    Lapa C; Lückerath K; Kleinlein I; Monoranu CM; Linsenmann T; Kessler AF; Rudelius M; Kropf S; Buck AK; Ernestus RI; Wester HJ; Löhr M; Herrmann K
    Theranostics; 2016; 6(3):428-34. PubMed ID: 26909116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4.
    Demmer O; Dijkgraaf I; Schumacher U; Marinelli L; Cosconati S; Gourni E; Wester HJ; Kessler H
    J Med Chem; 2011 Nov; 54(21):7648-62. PubMed ID: 21905730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [
    Li X; Yu W; Wollenweber T; Lu X; Wei Y; Beitzke D; Wadsak W; Kropf S; Wester HJ; Haug AR; Zhang X; Hacker M
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1616-1625. PubMed ID: 31004184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.
    Gourni E; Demmer O; Schottelius M; D'Alessandria C; Schulz S; Dijkgraaf I; Schumacher U; Schwaiger M; Kessler H; Wester HJ
    J Nucl Med; 2011 Nov; 52(11):1803-10. PubMed ID: 22045709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
    Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
    J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine receptor - Directed imaging and therapy.
    Buck AK; Stolzenburg A; Hänscheid H; Schirbel A; Lückerath K; Schottelius M; Wester HJ; Lapa C
    Methods; 2017 Nov; 130():63-71. PubMed ID: 28916148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Contrast CXCR4-Targeted
    Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
    Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI.
    Rischpler C; Nekolla SG; Kossmann H; Dirschinger RJ; Schottelius M; Hyafil F; Wester HJ; Laugwitz KL; Schwaiger M
    J Nucl Cardiol; 2016 Feb; 23(1):131-3. PubMed ID: 26667813
    [No Abstract]   [Full Text] [Related]  

  • 13. [
    Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
    Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
    Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
    Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.
    Lapa C; Lückerath K; Rudelius M; Schmid JS; Schoene A; Schirbel A; Samnick S; Pelzer T; Buck AK; Kropf S; Wester HJ; Herrmann K
    Oncotarget; 2016 Feb; 7(8):9288-95. PubMed ID: 26843617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 PET imaging of mantle cell lymphoma using [
    Mayerhoefer ME; Raderer M; Lamm W; Pichler V; Pfaff S; Weber M; Kiesewetter B; Hacker M; Kazianka L; Staber PB; Wester HJ; Rohrbeck J; Simonitsch-Klupp I; Haug A
    Theranostics; 2021; 11(2):567-578. PubMed ID: 33391493
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Bouter C; Meller B; Sahlmann CO; Staab W; Wester HJ; Kropf S; Meller J
    J Nucl Med; 2018 Feb; 59(2):320-326. PubMed ID: 28729430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [
    Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
    Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in PET Imaging of the CXCR4 Receptor: [
    Lindenberg L; Ahlman M; Lin F; Mena E; Choyke P
    Semin Nucl Med; 2024 Jan; 54(1):163-170. PubMed ID: 37923671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.
    Chen Z; Xue Q; Yao S
    Mini Rev Med Chem; 2023; 23(7):787-803. PubMed ID: 36529918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.